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ABSTRACT
Ectopic expression in T-cell precursors of LIM only protein 2 (LMO2), a key factor in 
hematopoietic development, has been linked to the onset of T-cell acute lymphoblastic 
leukaemia (T-ALL). In the T-ALL context, LMO2 drives oncogenic progression through 
binding to erythroid-specific transcription factor SCL/TAL1 and sequestration of 
E-protein transcription factors, normally required for T-cell differentiation. A key 
requirement for the formation of this oncogenic protein-protein interaction (PPI) is 
the conformational flexibility of LMO2. Here we identify a small molecule inhibitor of the 
SCL-LMO2 PPI, which hinders the interaction in vitro through direct binding to LMO2. 
Biophysical analysis demonstrates that this inhibitor acts through a mechanism of 
conformational modulation of LMO2. Importantly, this work has led to the identification 
of a small molecule inhibitor of the SCL-LMO2 PPI, which can provide a starting point 
for the development of new agents for the treatment of T-ALL. These results suggest 
that similar approaches, based on the modulation of protein conformation by small 
molecules, might be used for therapeutic targeting of other oncogenic PPIs.
INTRODUCTION
Stem cell leukaemia (SCL, also known as TAL-
1) is a basic helix-loop-helix transcription factor with 
essential, non-redundant roles in haematopoietic 
development and the terminal maturation of erythroid 
cell lineages [1, 2]. Central to SCL function is the ability 
to bind the haematopoietic transcription co-factor LIM-
only protein 2 (LMO2) [3]. LMO2 has multiple essential 
roles in erythroid differentiation, angiogenesis and CNS 
development [4–10]. Aberrant LMO2 expression due 
to chromosomal translocations or interstitial deletions 
[11–13] has been observed in multiple haematological 
malignancies, most notably T-cell acute lymphoblastic 
leukaemia (T-ALL) [4, 14]. Ectopic expression of SCL 
through chromosomal translocations or microdeletion or 
transactivation through abnormal expression of proteins 
within the haematopoietic regulatory network [15] 
is observed in ~60% of T-ALL cases of which ~40% 
also display abnormal LMO2 expression [10, 11]. The 
two proteins have been well characterised as acting 
synergistically to promote a phenotype of aberrant self-
renewal in T-cell precursors through formation of a 
multiprotein complex with essential roles in both normal 
and malignant haematopoiesis [3, 16, 17], driving a 
mechanism of E2A protein sequestration [10, 11, 16]. 
Additionally, dysregulation of LMO2 alone through 
somatic mutation [18] or resulting from retroviral 
activation mutagenesis following treatment for X-SCID 
[19] is recognised as an oncogenic promoter in T-ALL.
Studies of the pre-leukemic phenotype in mouse 
models suggest that both SCL and LMO2 overexpression 
causes T-ALL by inducing aberrant self-renewal of 
committed T-cells in the thymus, resulting in a cellular 
pool which can over time acquire additional gain-of-
function mutations of genes involved in signalling 
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pathways regulating T-cell development, such as NOTCH1, 
interleukin-7, KIT and FLT3 [20]. Relapse is associated 
with clonal evolution from a population of pre-leukemic 
stem cells that acquire the whole set of malignant mutations 
leading to a full-blown T-ALL. Numerous studies have 
suggested that SCL and LMO2 function cooperatively 
to drive this phenotype of aberrant self-renewal in T-cell 
precursors through a mechanism of functional sequestration 
of E2A-protein homodimers which are essential for normal 
T-cell differentiation [10, 11, 16, 21–26]. As the binding 
affinity of LMO2 for SCL/E2A-containing complexes 
is very high (Ka = 1.8 × 10
8 M-1), the sequestration of 
E2A proteins is strongly favoured in cells that express 
both SCL and LMO2 [27]. Current therapeutic options 
for the treatment of T-ALL are limited to an extended 
and aggressive program of cytotoxic chemotherapies 
and radiotherapies. While effective, these treatments are 
associated with significant, long-term adverse effects, 
particularly in young children. Additionally, patients 
presenting with relapsed T-ALL have a poor prognosis 
with current treatments. Targeting the critical SCL-LMO2 
protein-protein interaction (PPI) provides an alternative 
approach to developing novel therapeutics for these patients. 
We have previously solved the atomic structure 
of the SCLbHLH/E47bHLH – LMO2:LDB1
LID quaternary 
complex (hereafter referred to as the SCL-LMO2 complex) 
using X-ray crystallography [16] and mapped the binding 
interface by mutagenesis. This revealed that only a small 
number of amino acids contribute to the binding interface 
and that flexibility around hinge amino acid F88 is crucial 
for this PPI in vitro, in vivo and ex vivo [16, 28, 29]. Within 
this structural framework, we have used a combination 
of biophysical and biochemical techniques to screen for 
small molecules with the goal of developing compounds 
which can specifically inhibit the SCL LMO2 PPI. Using 
a homogeneous time-resolved fluorescence (HTRF) assay 
we have identified a dose-responsive hit compound (3K7), 
which inhibits the SCL-LMO2 PPI in vitro. We have 
used Saturation Transfer Difference Nuclear Magnetic 
Resonance (STD-NMR) and Microscale Thermophoresis 
(MST) to demonstrate that 3K7 binds LMO2 with 1.2 
µM affinity. Using Small Angle X-ray Scattering (SAXS) 
we demonstrate that 3K7 acts through a mechanism of 
structural modulation, locking LMO2 in a conformation 
that inhibits its interactions with SCL. Our work suggests 
that developing small molecules interfering with the 
conformational flexibility of LMO2 is a realistic and novel 
approach for the therapeutic targeting of T-ALL.
RESULTS
HTRF screen identifies dose-dependent 
inhibitors of SCL-LMO2 PPI
To identify initial inhibitors of the SCL-LMO2 
interaction in vitro, a homogeneous time-resolved 
fluorescence (HTRF) assay was established, using 
fluorophores conjugated to anti-His and anti-FLAG 
affinity antibodies to observe protein interactions 
(Figure 1A) [30]. Recognition of the affinity tags on the 
purified proteins by the antibodies acts to effectively 
fluorescently label each protein without compromising 
the interaction interface. Using anti-FLAG terbium 
cryptate as a donor fluorophore and anti-His-d2 as the 
acceptor fluorophore allows for detection of red-shifted 
fluorescence signals at a time delay, reducing background 
signals from compound autofluorescence and improving 
signal to noise ratios for the assay. 
SCL forms obligate heterodimers with its binding 
partner E47 through the bHLH domains of each protein. 
Co-expression of the SCLbHLH and E47bHLH domains results 
in a mixed population of SCL-E47 heterodimers and E47 
homodimers, which are indistinguishable by SEC. Cloning 
of an N-terminal Strep-II tag on SCLbHLH and purification 
with Strep-Tactin allowed isolation of the SCL-E47 
heterodimer species (Figure 1B) which was subsequently 
labelled with anti-His affinity antibody conjugated 
fluorophores. The LMO2:LDB1LID fusion protein previously 
used for structure determination by X-ray crystallography 
[16, 28, 31, 32] was cloned into a vector with a cleavable 
N-terminal 6xHis tag and a C-terminal FLAG tag. Following 
initial IMAC purification and cleavage of the His tag, the 
protein was isolated by size exclusion chromatography 
(SEC) prior to specific labelling of the protein with anti-
FLAG antibody conjugated fluorophores (Figure 1C).
Upon formation of the core quaternary complex 
(LMO2:LDB1LID-SCLbHLH/E47bHLH), the two fluorophores 
are brought into close proximity. Subsequent excitation 
of the terbium cryptate donor then results in Förster 
Resonance Energy Transfer (FRET) leading to detectable 
emissions from both fluorophores. Disruption of the 
complex through inhibition of the protein-protein 
interaction thus leads to a quantifiable decrease in 
FRET signals. The combination of donor and acceptor 
fluorophore, protein and antibody concentration and 
incubation times were determined experimentally, with 
the assay optimised for screening in 384 well plate format 
using automated liquid handling. 
Subsequently, the HTRF assay was used to screen 
a library of small molecules for activity as inhibitors of 
the SCL-LMO2 PPI. To maximise our potential hit rate 
from screening, the Protein-Protein Interactions Network 
(PPI-Net) library was used as it contains predominantly 
large, hydrophobic molecules which are typical of PPI 
inhibitors. 1534 compounds were screened at a single 
point concentration of 10 µM, with hits determined 
as resulting in a reduction in FRET ratio greater than 
three standard deviations from the plate mean over two 
independent replicates (Figure 2A). Statistical significance 
was determined by z’ score calculated using in-plate 
controls (DMSO vector (negative) and LMO2 only 
(positive) (Table 1). 
Oncotarget1739www.oncotarget.com
From the initial screen, two compounds were 
identified as reproducibly inhibiting the LMO2-SCL PPI 
with an additional six compounds observed to give a 
reduced FRET ratio in at least one replicate screen. The 
HTRF assay was repeated with these eight compounds to 
determine the dose-response (Supplementary Figure 1). 
From the initial eight, two compounds, 3K7 and 5C7, 
(Figure 2C, 2D) resulted in a reproducible, dose-dependent 
inhibition of the SCL-LMO2 PPI over 3 independent 
repeats with calculated IC50 values of 14.7 µM and 18.7 
µM respectively (Figure 2B). The compounds were 
repurchased from the source and purity and structural 
identity were confirmed by mass spectrometry and 1H 
NMR (Supplementary Figure 2) before re-testing in 
the HTRF assay. A similar profile of dose-dependent 
inhibition (data not shown) was observed, confirming that 
the identified small molecules act as inhibitors of the SCL-
LMO2 PPI in vitro.
3K7 acts through direct and specific interaction 
with LMO2 
To determine the mechanism of inhibition, we 
investigated the binding of 3K7 and 5C7 to LMO2 and 
SCL/E47 using ligand-observed STD-NMR [33, 34]. 
Peaks corresponding to the 1H spectrum of 3K7 were 
observed in the collected STD-NMR spectrum in the 
presence of LMO2, indicative of binding (Figure 3A). 
In comparison, no binding of compound 5C7 to LMO2 
was detected in these experiments (Figure 3B). To further 
investigate the mode of interaction of 3K7 and 5C7, 
we used microscale thermophoresis (MST) [35, 36]. 
Purified proteins were labelled on free amine residues 
with a NHS-647 dye (Nanotemper), and thermophoresis 
of labelled proteins was monitored in the presence of 
increasing concentrations of inhibitor. Analysis of the 
data revealed a dose-dependent interaction of 3K7 with 
Figure 1: Primary HTRF assay set up. (A) Schematic illustrating the principle of the HTRF assay. Formation of the quaternary 
protein complex SCL/E47-LMO2:LDB1LID brings affinity antibody conjugated fluorophores into proximity. Subsequent excitation of the 
donor fluorophore results in energy transfer and excitation of the acceptor fluorophore. Emissions from both fluorophores can be detected 
and quantified to determine the FRET ratio. Disruption of complex formation by small molecule binding results in a quantifiable reduction 
in FRET signals. (B) SDS-PAGE analysis of SCL-E47 heterodimer purification. Top panel: Fractions from His purification showing mixed 
homo- and hetero-dimers. Bottom panel: Fractions from strep purification showing isolated heterodimers. IN = input, F = flow through, 
W = wash, E = elution. (C) SDS-PAGE and Coomassie staining (top) or western blotting with anti-FLAG (middle) or anti-His (bottom) 
antibodies show complete removal of an N-terminal His tag from LMO2:LDB1LID-FLAG following incubation with HRV 3C protease 
(uncut vs. 3C treated lanes). 
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LMO2, with a calculated Kd of 1.2 µM (Figure 3C). No 
clear binding was observed with SCL, suggesting that the 
mechanism of inhibition is through a direct interaction 
with LMO2 (Figure 3D). In contrast, compound 5C7 
was observed to induce dose-dependent changes in 
the protein fluorescence, likely caused by non-specific 
binding or compound-induced aggregation of the proteins 
(Supplementary Figure 3). From these data, we conclude 
that the identified SCL-LMO2 PPI inhibitor, 3K7, acts 
through a direct interaction with LMO2.
In further experiments we addressed the specificity 
of the 3K7 interaction with LMO2. MST experiments were 
Table 1: HTRF assay parameters
Screen 1 Screen 2 Average
Mean FRET ratio 9899.57 9628.42 9764.00
Std deviation 1077.75 1282.27 1179.51
CV % 10.89 13.17 12.03
dF % 502.71 354.39 424.05
z’ 0.55 0.41 0.48
Total hits 7 15 11
Repeated hits 2 2 2
Figure 2: Primary HTRF screen identified dose-dependent inhibitors of the SCL-LMO2 PPI. (A) Representative example 
of the FRET ratio data collected for each 384 well plate. The plate mean (blue line) and three standard deviations above (green line) and 
below (red line) the mean are indicated. Hits are determined as yielding FRET ratios > 3σ below the plate mean. (B) Non-linear regression 
analysis of FRET inhibition by 3K7 (red) and 5C7 (blue) over a concentration gradient. Curves are the average of three independent 
replicates. Error bars represent standard deviation. Positive (no SCL, black) and negative (DMSO vector, green) controls are shown. (C) 
Chemical structure of compound 3K7 and (D) 5C7.
Oncotarget1741www.oncotarget.com
repeated to determine the affinity of 3K7 for the other 3 
known members of the LMO family: LMO1, LMO3 and 
LMO4. LMO2 shares ~50% sequence homology with 
LMO1 and LMO3, and < 40% with LMO4. The crystal 
structures of LMO2 [28, 31] and LMO4 [37, 38] showed 
strong structural homology of the individual LIM domains 
(128 residues superimposing within an RMSD of 2.7 
Å) and more extensive structural homology is expected 
between LMO2, LMO1 and LMO3. From the functional 
point of view, LMO1, LMO2 and LMO3 have been 
associated with haematopoiesis and T-ALL, whilst LMO4 
is functionally more divergent.
The MST analysis showed no interaction between 
3K7 and LMO1, LMO3 or LMO4 (Figure 4). Taken 
together our data indicate that 3K7 forms a direct and 
specific interaction with LMO2. 
3K7 induced conformational change in LMO2 
comparable to SCL-binding deficient mutant
To further elucidate the potential mechanism of 
3K7-mediated inhibition of the SCL-LMO2 interaction, 
we set out to investigate the impact of 3K7 binding on the 
conformational flexibility of LMO2. 
Previously published crystallography data [16, 28] 
revealed large movements around a conserved hinge 
(F88) between the LIM domains. Mutation of the hinge 
residue (F88D) demonstrated that this residue is absolutely 
required for binding of LMO2 to its partner protein SCL/
TAL1 in vitro and for the function of this complex in vivo. 
As this residue is located in proximity of the SCL interface, 
it is possible that mutation of this residue disrupts the 
binding surface. Another possibility is that a mutation in 
Figure 3: 3K7 binds directly to LMO2. STD-NMR spectra for compound alone (green) or in complex with LMO2 (red) were 
compared to reference 1H spectra (blue) for (A) 3K7 and (B) 5C7. Box highlights peaks indicative of binding observed in the aromatic 
region of the 3K7 spectrum. (C) Curve showing normalised fluorescence data from MST experiments with LMO2 and (D) SCL/E47 in 
presence of increasing 3K7 concentration. The bottom panel in C shows residuals between the data and the fit line. Error bars represent 
standard deviation, n = 4.
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the hinge region affects the accessible conformations of 
the proteins. The effect of the F88D mutation on LMO2 
conformation was explored using small angle X-ray 
scattering (SAXS) to observe the protein in solution 
[39, 40]. Firstly, circular dichroism spectroscopy (CD) 
determined that the F88D is soluble and correctly folded 
with no significant deviation observed from the WT profile 
suggesting no changes in the secondary structure (Figure 
5A). Next, WT and F88D were subjected to SEC-SAXS 
to obtain information on the shape and the size of these 
proteins. By using a Kratky representation to evaluate the 
globularity and flexibility, we observe that LMO2 and 
F88D have similar scattering profiles and are multidomain 
proteins connected by a flexible linker (Figure 5B). 
Analysis of the pair-wise distance distribution function 
P(r) however, showed a reduced in the maximum distance 
(Dmax) of F88D (Figure 5C) and of the calculated radius of 
gyration (Rg) (Table 2) when comparing F88D to LMO2, 
suggesting that the mutant protein on average adopts 
a more constrained conformation. The data therefore 
suggests that the F88D mutation causes modulation of the 
LMO2 conformational flexibility.
We hypothesised that 3K7 exercises its inhibitory 
effect through a similar mechanism of conformational 
modulation. Addition of increasing concentrations of 3K7 to 
WT prior to the SAXS experiments resulted in a shift of the 
protein Dmax (Figure 5C) and Rg (Table 2) to values similar 
to those of F88D, suggesting that in solution the proteins 
adopts a constrained conformation, similar to that of F88D. 
Next, we hypothesised that 3K7 is a conformation-specific 
ligand, binding to LMO2 only in its SCL-binding competent 
form. To test this hypothesis, we investigated binding of 3K7 
to F88D. Over multiple repeats, no evidence of compound 
binding was observed (Figure 5D), supporting the suggestion 
that the conformational state adopted by LMO2 following 
the F88D mutation is not compatible with 3K7 binding. 
Table 2: Structural parameters from SAXS
LMO2 LMO2-F88D LMO2+3K7 (1.5) LMO2+3K7 (3)
Rg (Å) 38.85 36.56 38.32 38.03
Dmax (Å) 140 122 136 124
χ2 1.06 1.47 0.98 0.89
Figure 4: 3K7 does not bind to other LMO family proteins. Curves showing normalised fluorescence data from MST experiments 
looking at 3K7 binding to LMO1 (pink), LMO3 (blue), LMO4 (violet). Error bars represent standard deviation, n = 3.
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DISCUSSION
Protein-protein interactions are challenging, yet 
potentially valuable targets for drug discovery. A particular 
attractive strategy in the quest to design novel anticancer 
agents is to target transcription factors PPIs, as TF operate 
at junction points in most oncogenic signalling pathways 
and are often functionally altered in many cancers. 
Targeting PPIs by small molecule inhibitors however has 
historically been considered a challenging undertaking. 
Large surface areas and the lack of pockets at the PPI 
interface have elicited the long-held belief that this class 
of interactions is “undruggable”. The paradigm is however 
shifting, in part thanks to recent advances in biophysical 
and structural techniques, which have provided clearer 
insights into PPI interactions. These studies have clearly 
established that the bulk of the binding energy at PPI 
interfaces is provided only by a small subset of amino 
acids and that targeting these “hot spots” is likely to 
destabilise the interaction. An ever-increasing number 
of success stories of small molecules modulators of PPI 
bodes well for structure-based approaches to this [41–43]. 
When considering inhibiting transcription factors’ 
PPIs, two main approaches have been explored: disrupting 
(homo or hetero) dimerization, or targeting interactions 
with other transcriptional cofactors. Whilst the first 
approach is likely to abolish function by blocking DNA 
binding, the second has the potential to modulate function 
by inhibiting potential oncogenic interactions. 
In T-ALL, ectopically expressed transcription factor 
SCL interacts with transcriptional cofactor LMO2 to 
prevent the activity of E protein homodimers, essential 
for normal progression of T-cell differentiation. Detailed 
analysis of the SCL-LMO2 PPI interface, as revealed by 
the crystal structure of the complex, uncovered a small 
interface area (620 Å2) suggesting that the bulk of the 
binding energy is provided only by a small subset of 
amino acids around the hinge domains of LMO2 and that 
targeting this “hot spot” by small molecules is likely to 
destabilise this T-ALL oncogenic interaction. 
Figure 5: 3K7 induces a change in LMO2 conformation comparable to LMO2-F88D. (A) Comparison of the far-UV CD 
spectra for LMO2 (green) and F88D (gray) shows profiles consistent with folded proteins containing similar secondary structures elements. 
(B) Kratky plot of the solution scattering showing broad bell-shaped curves typical of elongated, flexible protein molecules (green: LMO2; 
gray: LMO2-F88D; light blue: LMO2+ 1.5x 3K7; red: LMO2+3x 3K7). (C) Overlay of the P(r) distribution curves characterizing LMO2 
(green), LMO2-F88D (gray), and LMO2 incubated with 1.5× (light blue) and 3× (red) molar concentrations of 3K7. The goodness of 
the data fitting was assessed by calculation of the χ2 value, with best fit approximating to 1. The shape of curves is characteristic for 
elongated molecules. (D) Curve showing normalised fluorescence data from MST experiments with LMO2-F88D with increasing 3K7 
concentrations. Error bars represent standard deviation, n = 3.
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To find small molecules capable of disrupting the 
SCL-LMO2 interaction we used HTRF as a primary 
screen. Labelling proteins with fluorophores conjugated 
to affinity antibodies allows for monitoring of complex 
formation and subsequent FRET emission, without 
compromise of the interaction interface when compared 
to covalent modification of the proteins. HTRF can be 
easily optimised for automated liquid handling allowing 
rapid screening of large compound libraries. Use of a 
specific PPI library designed to target larger, hydrophobic 
interfaces provided an increased probability of identifying 
hits. From the primary screens, two molecules were 
identified as dose-responsive SCL-LMO2 PPI inhibitors, 
an acceptable 0.13% hit rate, following hit reconfirmation 
(purity and structure confirmation). However, following 
these encouraging biochemical screening data, it was 
essential to provide confirmatory, orthogonal evidence of 
disruption of the SCL-LMO2 interaction.
One of these compounds, 3K7, was found to be 
directly and specifically binding to LMO2 but not to other 
members of the LMO family. The low solubility of the 3K7 
meant that further structural biology techniques (X-ray 
crystallography, NMR) aimed at ascertaining the molecular 
details of its interaction with LMO2 were not successful. By 
using SAXS, we were able to demonstrate that 3K7 appears 
to modulate the conformational flexibility of LMO2, 
with the protein adopting a less extended conformation. 
Previous work uncovered substantial conformational 
flexibility of LMO2 around the conserved hinge between 
the LIM domains which proved necessary for binding SCL. 
Specifically, mutation of F88 in the hinge domain induced 
a conformational change in LMO2 which prevented it from 
binding to SCL. Our SAXS data suggest that 3K7 binding 
to LMO2 alters the conformational flexibility of LMO2 
in a comparable way to the F88D mutation, leading us to 
speculate that conformational modulation is the mechanism 
of action of this small molecule drug.
Our MST data shows that 3K7 has little affinity for 
other member of the LMO family, implying that 3K7 is 
LMO2 specific. Structural analysis of the atomic structures 
had previously suggested that despite highly homologous 
secondary structure arrangements, widely different 
conformational states were adopted by LMO2 and LMO4 
around their hinge domains. Sequence divergence of LMO 
proteins is likely to be responsible for the alternative 
conformational states, thus regulating the varied PPIs 
they are thought to be mediating. This provides a potential 
explanation for the specificity of 3K7 for LMO2 over the 
closely related LMO proteins and further could allow for 
specific targeting. This hypothesis is further supported by 
the observation that 3K7 is unable to bind to the F88D 
LMO2 mutant, which like LMO4 adopts a distinct subset 
of conformations when compared to WT LMO2.
The low aqueous solubility of 3K7 prevented 
additional cellular assays to be performed, restricting the 
prospect of testing this compound in vivo. Low solubility 
also prevented a more in depth structural analysis of 
the binding mode of 3K7, limiting further chemical 
development of the compound. Nonetheless, our data 
provide evidence that the effect of small molecules on 
modulating protein conformation can be potentially 
used as a powerful approach to drug discovery, even 
for otherwise intractable PPIs. Specifically, as protein 
conformation is key to mediating PPIs between flexible, 
minimally structured proteins, future work could exploit 
this reliance on conformational flexibility to engineer 
specific therapeutics that target transcription factors.
However, we posit that not all PPIs are equally 
tractable for blocking by small molecules that modulate 
conformational flexibility and detailed analysis of PPI 
interfaces is critical for selection of those with the highest 
chance of success.
MATERIALS AND METHODS
Materials
A library of 1534 compounds was obtained from 
PPI-net. Additional compounds were purchased from 
suppliers (3K7 – Asinex, 5C7 – ChemDiv). 
Expression constructs
A tandem LIM-domain construct of LMO2 
fused to the LDB1LID (FLINC2, [31]) was used for CD 
spectroscopy and MST. The protein was subcloned into a 
pET47b vector containing a HRV 3C cleavable N-terminal 
6x-His tag by Gibson Assembly to allow production of 
untagged protein for NMR and SAXS (pET47-LMO2), 
and subsequently a C-terminal FLAG tag was introduced 
by PCR for HTRF (LMO2-FLAG). 
The F88D mutation was introduced into each 
construct as required by site-directed mutagenesis using 
standard PCR protocols [16].
The bHLH domains of SCL and E47 are co-
expressed from one construct (pETDuet-E47/SCL, [16]). 
An N-terminal Strep-II tag was introduced to the SCL 
sequence by PCR. 
Tandem-LIM domain constructs of LMO1 (aa 20-
149), LMO3 (aa 9-139) fused to the LDB1LID (aa 336-375) 
in the pETDuet vector were used for MST as specified in 
the results. A tandem-LIM construct of LMO4 (aa 16-152, 
including C52S/C64S mutations) fused to the LDB1LID (aa 
336-375) [37] in the pET47b(+) vector was also used for 
MST as specified. 
Protein expression and purification 
LMO2 proteins were expressed in E.coli and 
purified as previously published [31]. For HTRF 
experiments, cleavable His-tags were removed by 
overnight incubation at 4°C with HRV-3C protease prior 
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to SEC purification. Other LMO proteins were expressed 
and purified as LMO2. 
SCL protein was co-expressed with E47 in E.coli 
as previously published [16]. Initial purification on cobalt 
resin (Generon) in IMAC buffer (50 mM sodium phosphate 
pH 8, 500 mM NaCl, 0.5 mM TCEP) eluting in 300 mM 
imidazole, followed by purification on StrepTactin (GE 
Healthcare) eluting in 2.5 mM desthiobiotin (Sigma) 
yielded isolated His-E47/Strep-SCL heterodimers. 
Additional SEC purification using Superdex75 columns 
(GE Healthcare) was carried out as required in SEC buffer 
(20 mM HEPES pH 7.4, 200 mM NaCl, 0.5 mM TCEP). 
Homogeneous Time-Resolved Fluorescence 
(HTRF) 
Small molecules from a 1534 compound library (PPI-
net) were transferred to 384 well plates (2 µL each 50 µM 
stock in HTRF buffer (25 mM HEPES pH 7.5, 250 mM 
NaCl) plus 5% DMSO, final concentration 10 µM) using a 
FluidX XPP-721 automated liquid handling system. Purified 
LMO2-FLAG and His-E47/Strep-SCL proteins were diluted 
to 250 nM in HTRF buffer and mixed 1:1 immediately prior 
to use. 8 µL mixed proteins were added to each well to a final 
concentration of 100 nM using a Multidrop Combi reagent 
dispenser (Thermo Fisher Scientific) and plates were incubated 
at room temperature for 2 hours at room temperature. Control 
wells (maximum FRET: mixed proteins + DMSO; no FRET: 
LMO2 + DMSO) were included on each plate. Fluorophore-
conjugated affinity antibody stocks (anti-FLAG terbium 
cryptate, anti-His-d2, CisBio) were diluted 1:100 in HTRF 
buffer before mixing 1:1 and adding to 384 well plates (10 µL/
well, Multidrop Combi). Plates were incubated for a further 
2 hours at room temperature before detecting FRET signals 
using a PHERAstar FS (BMG LabTech) plate reader with 
HTRF 337/620/655 nm optic module installed. Excitation 
at 337 nm was carried out using an integration delay of 60 
µsec, integration time 400 µsec, 40 flashes (laser), with an 
automatically determined focal height. Emissions at 620 and 
655 nm were measured to calculate the FRET ratio dF%. Hits 
were determined as giving a reduction in FRET ratio > 3 SD 
from plate mean over 2 independent repeats. Significance 
was determined by calculating z’ score for each plate/data set 
[44]. To check for the effect of DMSO, FRET ratio dF% was 
measured by mixing 50 nM of each protein and 5 μL of each 
antibodies with increasing concentrations of DMSO (0, 1, 2, 
5, 10% DMSO) and reading the plate at 0, 1, 2 and 3 hours 
after addition of the antibodies. A decrease in HTRF signal 
with the addition of any percentage of DMSO was recorded, 
but no significant difference in signal with concentrations 
between 1–10% at each time point (Supplementary Figure 
4). Dose-response of selected compounds was determined 
over 10 3-fold serial dilutions from 100 µM. Data from three 
independent repeats was analysed by non-linear regression 
(GraphPad Prism), error bars represent standard deviation 
from 3 independent repeats. 
Microscale Thermophoresis (MST) 
Purified proteins were individually labelled with 
fluorescent dye NT647 using a Monolith NTTM Protein 
Labeling Kit (NanoTemper Technologies). Serial dilutions 
of 3K7 and 5C7 (100 µM–6 nM) in MST buffer (50 
mM Tris-HCl pH 7.8, 150 mM NaCl, 10 mM MgCl2, 
0.05% Tween 20, 2% DMSO) were mixed with 100 
nM NT647-labeled protein, incubated for 15 minutes 
at room temperature and loaded into standard glass 
capillaries (Monolith NT.115 Capillaries, NanoTemper 
Technologies). Thermophoresis analysis was performed 
over 30 seconds on a Monolith NT.115 instrument (20% 
LED, 20/40% MST power) at 22°C. The MST curves 
were fitted using NT Analysis software (NanoTemper 
Technologies) to obtain Kd values for binding. 
For SD-tests, MST samples were mixed 1:1 with 
2X SD mix (4% SDS, 40 mM DTT) and incubated at 95 
°C for 5 minutes to denature. Following centrifugation, 
samples were loaded into standard glass capillaries and the 
fluorescence intensity was re-tested. 
Saturation-Transfer Difference NMR (STD-
NMR) 
STD-NMR experiments [34] were performed on 
a Bruker Advance III 900 MHz spectrometer equipped 
with a 5 mm cryogenic probe at 25ºC. Samples contained 
100 mM compounds and 5 µM LMO2 protein. Selective 
saturation of the protein was achieved using a train of 
Gaussian pulses at –0.5 ppm for a total saturation time 
of 3s. Off-resonance irradiation was set at 30 ppm. Data 
were collected using 32k complex points in the direct 
dimension. 512 scans were collected for each experiment 
and a interscan delay of 3 seconds was used to allow 
relaxation of the sample. Water suppression was achieved 
using excitation sculpting. 
CD spectroscopy 
Far-UV CD analysis of LMO2 and LMO2-F88D 
proteins was performed on a Jasco J715 Spectropolarimeter. 
The spectra were recorded over wavelength range 190–280 
nm in a 0.1 mm cell at sample concentration of 30 µM at 
21°C in CD buffer (20 mM HEPES pH 7.5, 100 mM NaF). 
The final spectra were the average of 3 scans. CD spectra 
of the buffer solutions in the appropriate cuvette were 
subtracted from the sample spectra and smoothed using the 
Savistky–Golay function before conversion to absolute CD 
values. Curves were generated in Excel.
Small Angle X-ray Scattering (SAXS) 
Purified LMO2 and LMO2-F88D proteins were 
diluted to 40 µM in SAXS buffer (20 mM HEPES pH 
7.5, 200 mM NaCl, 0.5 mM TCEP). 3K7 was added as 
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required (1.5 and 3 molar equivalents, 1% DMSO final) 
before incubation for 1 hour at room temperature. X-ray 
scattering patterns were recorded from solutions of the 
individual proteins on beamline B21 at Diamond Light 
Source. Samples were run through a Shodex KW402.5 
column with an Agilent FPLC at 0.16 mL/min and then 
applied directly into the beam. Scattering was recorded on 
a Pilatus 2M detector with a 0.2 × 0.2 mm, 12.4 KeV (1 Å) 
beam. Sample to detector distance set at 4000 mm, exposure 
time of 3 seconds (10 readings/exposure in HPLC mode) at 
293 K. Data processing (background subtraction and radius 
of gyration (Rg) calculation) was performed using ScÅtter 
(v3.0 by Robert P. Rambo; Diamond Light Source).
Data availability
All data needed to evaluate the conclusions in the 
paper are present in the paper and/or the Supplementary 
Materials. Additional data related to this paper may be 
requested from the authors.
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